


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/54, 15/70, 9/12, 1/21, C12Q 1/68 // (C12N 1/21, C12R 1:19)		A1	(11) International Publication Number: WO 96/10640
(21) International Application Number: PCT/US95/12358		(43) International Publication Date: 11 April 1996 (11.04.96)	
(22) International Filing Date: 2 October 1995 (02.10.95)		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 08/316,423 30 September 1994 (30.09.94) US 08/370,190 9 January 1995 (09.01.95) US		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. With an indication in relation to a deposited microorganism furnished under Rule 13 ^{bis} separately from the description. Date of receipt by the International Bureau: 31 January 1996 (31.01.96)	
(71) Applicant: LIFE TECHNOLOGIES, INC. [US/US]; 8717 Grovemont Circle, Gaithersburg, MD 20884-9980 (US).			
(72) Inventors: HUGHES, A., John, Jr.; 19444 St Johnsbury Lane, Germantown, MD 20876 (US). CHATTERJEE, Deb, K.; 6 Forest Ridge Court, N. Potomac, MD 20878 (US).			
(74) Agents: ESMOND, Robert, W. et al.; Sterne, Kessler, Goldstein & Fox, Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).			

(54) Title: CLONED DNA POLYMERASES FROM THERMOTOGA NEAPOLITANA AND MUTANTS THEREOF

(57) Abstract

The invention relates to a substantially pure thermostable DNA polymerase from *Thermotoga neapolitana* (Tne) and mutants thereof. The Tne DNA polymerase has a molecular weight of about 100 kilodaltons and is more thermostable than Taq DNA polymerase. The mutant Tne DNA polymerase has at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3' → 5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5' → 3' exonuclease activity of said DNA polymerase; (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides. The present invention also relates to the cloning and expression of the wild type or mutant Tne DNA polymerase in *E. coli*, to DNA molecules containing the cloned gene, and to host cells which express said genes. The Tne DNA polymerase of the invention may be used in well-known DNA sequencing and amplification reactions.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
	Central Africa		Democratic Republic of		Jordan
	Congo		South Korea		Sweden
CH	Switzerland		Republic of Korea		Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

CLONED DNA POLYMERASES FROM THERMOTOGA
NEAPOLITANA AND MUTANTS THEREOF

5

10

Background of the Invention

Field of the Invention

15

The present invention relates to a substantially pure thermostable DNA polymerase. Specifically, the DNA polymerase of the present invention is a *Thermotoga neapolitana* DNA polymerase having a molecular weight of about 100 kilodaltons. The present invention also relates to the cloning and expression of the *Thermotoga neapolitana* DNA polymerase in *E. coli*, to DNA molecules containing the cloned gene, and to hosts which express said genes. The DNA polymerase of the present invention may be used in DNA sequencing and amplification reactions.

20

25

This invention also relates to mutants of the *Thermotoga neapolitana* (Tne) DNA polymerase, having substantially reduced 3'-5' exonuclease activity, mutants of *Thermotoga neapolitana* containing a Phe⁶⁷-Tyr⁶⁷ (as numbered in Fig. 5) mutation resulting in the ability of the mutant DNA polymerase to incorporate deoxynucleotides into a DNA molecule about as efficiently as deoxynucleotides; and mutants having substantially reduced 5'-3' exonuclease activity. The Tne mutants of this invention can have one or more of these properties. These Tne DNA polymerase mutants may also be used in DNA sequencing and amplification reactions.

Background Information

DNA polymerases synthesize the formation of DNA molecules which are complementary to a DNA template. Upon hybridization of a primer to the single-stranded DNA template, polymerases synthesize DNA in the 5' to 3' direction, successively adding nucleotides to the 3'-hydroxyl group of the growing strand. Thus, in the presence of deoxyribonucleoside triphosphates (dNTPs) and a primer, a new DNA molecule, complementary to the single stranded DNA template, can be synthesized.

A number of DNA polymerases have been isolated from mesophilic microorganisms such as *E. coli*. A number of these mesophilic DNA polymerases have also been cloned. Lin *et al.* cloned and expressed T4 DNA polymerase in *E. coli* (*Proc. Natl. Acad. Sci. USA* 84:7000-7004 (1987)). Tabor *et al.* (U.S. Patent No. 4,795,699) describes a cloned T7 DNA polymerase, while Minkley *et al.* (*J. Biol. Chem.* 259:10386-10392 (1984)) and Chatterjee (U.S. Patent No. 5,047,342) described *E. coli* DNA polymerase I and the cloning of T5 DNA polymerase, respectively.

Although DNA polymerases from thermophiles are known, relatively little investigation has been done to isolate and even clone these enzymes. Chien *et al.*, *J. Bacteriol.* 127:1550-1557 (1976) describe a purification scheme for obtaining a polymerase from *Thermus aquaticus* (Taq). The resulting protein had a molecular weight of about 63,000 daltons by gel filtration analysis and 68,000 daltons by sucrose gradient centrifugation. Kaledin *et al.*, *Biokhimiya* 45:644-51 (1980) disclosed a purification procedure for isolating DNA polymerase from *T. aquaticus* YT1 strain. The purified enzyme was reported to be a 62,000 dalton monomeric protein. Gelfand *et al.* (U.S. Patent No. 4,889,818) cloned a gene encoding a thermostable DNA polymerase from *Thermus aquaticus*. The molecular weight of this protein was found to be about 86,000 to 90,000 daltons.

Simpson *et al.* purified and partially characterized a thermostable DNA polymerase from a *Thermotoga* species (*Biochem. Cell. Biol.* 86:1292-1296 (1990)). The purified DNA polymerase isolated by Simpson *et al.* exhibited a

molecular weight of 85,000 daltons as determined by SDS-polyacrylamide gel electrophoresis and size-exclusion chromatography. The enzyme exhibited half-lives of 3 minutes at 95°C and 60 minutes at 50°C in the absence of substrate and its pH optimum was in the range of pH 7.5 to 8.0. Triton X-100 appeared to enhance the thermostability of this enzyme. The strain used to obtain the thermostable DNA polymerase described by Simpson *et al.* was *Thermotoga* species strain FjSS3-B.1 (Hussar *et al.*, *FEMS Microbiology Letters* 37:121-127 (1986)). Other DNA polymerases have been isolated from thermophilic bacteria including *Bacillus stearothermophilus* (Stenes *et al.*, *Biochim. Biophys. Acta* 272:156-166 (1972); and Kaboev *et al.*, *J. Bacteriol.* 145:21-26 (1981)) and several archaeobacterial species (Rossi *et al.*, *System. Appl. Microbiol.* 7:337-341 (1986); Klimczak *et al.*, *Biochemistry* 25:4850-4855 (1986); and Elie *et al.*, *Eur. J. Biochem.* 178:619-626 (1989)). The most extensively purified archaeobacterial DNA polymerase had a reported half-life of 15 minutes at 87°C (Elie *et al.* (1989), *supra*). Innis *et al.*, In *PCR Protocol: A Guide To Methods and Amplification*, Academic Press, Inc., San Diego (1990) noted that there are several extreme thermophilic eubacteria and archaeobacteria that are capable of growth at very high temperatures (Bergquist *et al.*, *Biotech. Genet. Eng. Rev.* 5:199-244 (1987); and Kelly *et al.*, *Biotechnol Prog.* 4:47-62 (1988)) and suggested that these organisms may contain very thermostable DNA polymerases.

In many of the known polymerases, the 5'-3' exonuclease activity is present in the N-terminal region of the polymerase. (Ollis, *et al.*, *Nature* 313:762-766 (1985); Freemont *et al.*, *Proteins* 1:66-73 (1986); Joyce, *Cur. Opin. Struct. Biol.* 1:123-129 (1991).) There are some conserved amino acids that are thought to be responsible for the 5'-3' exonuclease activity. (Gutman & Orlinton, *Nucl. Acids Res.* 21:4406-4407 (1993)) These amino acids include Tyr²², Gly¹⁰³, Gly¹⁸⁷, and Gly¹⁸⁸ in *E. coli* polymerase I. Any mutation of these amino acids would reduce 5'-to-3' exonuclease activity. It is known that the 5'-exonuclease domain is dispensable. The best known example is the Klenow fragment of *E. coli* polymerase I. The Klenow fragment is a natural proteolytic fragment devoid of

5'-exonuclease activity (Joyce *et al.*, *J. Biol. Chem.* 257:1958-64 (1990).) Polymerases lacking this activity are useful for DNA sequencing.

Most DNA polymerases also contain a 3'-5' exonuclease activity. This exonuclease activity provides a proofreading ability to the DNA polymerase. A
5 T5 DNA polymerase that lacks 3'-5' exonuclease activity is disclosed in U.S. Patent No. 5,270,179. Polymerases lacking this activity are useful for DNA sequencing.

The polymerase active site, including the dNTP binding domain is usually present at the carboxyl terminal region of the polymerase (Ollis *et al.*, *Nature*
10 313:762-766 (1985); Freemont *et al.*, *Proteins* 1:66-73 (1986)). It has been shown that Phe⁷⁶² of *E. coli* polymerase I is one of the amino acids that directly interacts with the nucleotides (Joyce & Steitz, *Ann. Rev. Biochem.* 63:777-822 (1994); Astatke, *J. Biol. Chem.* 270:1945-54 (1995)). Converting this amino acid to a Tyr results in a mutant DNA polymerase that does not discriminate against
15 dideoxynucleotides and is highly processive. See copending U.S. Application No. 08/525,087, of Deb K. Chatterjee, filed September 8, 1995, entitled "Mutant DNA Polymerases and the Use Thereof," which is expressly incorporated herein by reference.

Thus, there exists a need in the art to develop thermostable processive
20 DNA polymerases. There also exists a need in the art to obtain wild type or mutant DNA polymerases that are devoid of exonuclease activities and are non-discriminating against dideoxynucleotides.

Summary of the Invention

The present invention satisfies these needs in the art by providing additional DNA polymerases useful in molecular biology. Specifically, this invention includes a thermostable DNA polymerase having a molecular weight of about 100 kilodaltons. More specifically, the DNA polymerase of the invention is isolated from *Thermotoga neapolitana* (Tne). The *Thermotoga* species preferred for isolating the DNA polymerase of the present invention was isolated

from an African continental solfataric spring (Windberger *et al.*, *Arch. Microbiol.* 151. 506-512, (1989)).

The Tne DNA polymerase of the present invention is extremely thermostable, showing more than 50% of activity after being heated for 60 minutes at 90°C with or without detergent. Thus, the DNA polymerase of the present invention is more thermostable than Taq DNA polymerase.

The present invention is also directed to cloning a gene encoding a *Thermotoga neapolitana* DNA polymerase enzyme. DNA molecules containing the Tne DNA polymerase gene, according to the present invention, can be transformed and expressed in a host cell to produce a Tne DNA polymerase having a molecular weight of 100 kilodaltons. Any number of hosts may be used to express the *Thermotoga* DNA polymerase gene of the present invention; including prokaryotic and eukaryotic cells. Preferably, prokaryotic cells are used to express the DNA polymerase of the invention. The preferred prokaryotic hosts according to the present invention is *E. coli*.

The Tne DNA polymerase of the invention may be used in well known DNA sequencing (dideoxy DNA sequencing, cycle DNA sequencing of plasmid DNAs, etc.) and DNA amplification reactions.

The present invention is also directed to mutant thermostable DNA polymerases. More specifically, the mutant DNA polymerases of the invention are derived from *Thermotoga neapolitana* and are substantially reduced or devoid of 3'-5' exonuclease activity, 5'-3' exonuclease activity, or is nondiscriminating against dideoxynucleotides. The present invention also relates to mutants having more than one of these properties, and DNA molecules containing the mutant Tne DNA polymerase enzyme genes. These mutants may also be used in well known DNA sequencing and DNA amplification reactions

Brief Description of the Figures

Figure 1 demonstrates the heat stability of Tne DNA polymerase at 90°C over time. Crude extract from *Thermotoga neapolitana* cells was used in the assay.

5 Figure 2 shows the DNA polymerase activity in crude extracts from an *E. coli* host containing the cloned Tne DNA polymerase gene.

Figure 3 compares the ability of various DNA polymerases to incorporate radioactive dATP and [α S]dATP. Tne DNA polymerase is more effective at incorporating [α S]dATP than was *Taq* DNA polymerase.

10 Figure 4 shows the restriction map of the approximate DNA fragment which contains the Tne DNA polymerase gene in pSport 1 and pUC19. This figure also shows the region containing the O-helix homologous sequences.

15 Figure 5 shows the nucleotide and deduced amino acid sequences, in all 3 reading frames, for the carboxyl terminal portion, including the O-helix region, of the *Thermotoga neapolitana* polymerase gene.

Figure 6A schematically depicts the construction of plasmids pUC-Tne (3'-5') and pUC-Tne FY.

Figure 6B schematically depicts the construction of plasmids pTrc Tne35 and pTrcTne FY.

20 Figure 7 schematically depicts the construction of plasmid pTrcTne35 FY and pTrcTne535FY.

Figure 8 schematically depicts the construction of plasmid pTTQTne5 FY.

Detailed Description of the Preferred Embodiments

Definitions

In the description that follows, a number of terms used in recombinant DNA technology are extensively utilized. In order to provide a clearer and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

Cloning vector. A plasmid, cosmid or phage DNA or other DNA molecule which is able to replicate autonomously in a host cell, and which is characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the vector, and into which DNA may be spliced in order to bring about its replication and cloning. The cloning vector may further contain a marker suitable for use in the identification of cells transformed with the cloning vector. Markers, for example, are tetracycline resistance or ampicillin resistance.

Expression vector. A vector similar to a cloning vector but which is capable of enhancing the expression of a gene which has been cloned into it, after transformation into a host. The cloned gene is usually placed under the control of (i.e., operably linked to) certain control sequences such as promoter sequences.

Recombinant host. Any prokaryotic or eukaryotic or microorganism which contains the desired cloned genes in an expression vector, cloning vector or any DNA molecule. The term "recombinant host" is also meant to include those host cells which have been genetically engineered to contain the desired gene on the host chromosome or genome.

Host. Any prokaryotic or eukaryotic or microorganism capable of receiving a replicable expression vector, cloning vector or any DNA molecule. The DNA molecule may contain, but is not limited to, a structural gene, a promoter and/or an origin of replication.

Promoter. A DNA sequence generally described as the 5' region of a gene, located proximal to the start codon. At the promoter region, transcription of an adjacent gene(s) is initiated.

5 **Gene.** A DNA sequence that contains information necessary for expression of a polypeptide or protein. It includes the promoter and the structural gene as well as other sequences involved in expression of the protein.

Structural gene. A DNA sequence that is transcribed into messenger RNA that is then translated into a sequence of amino acids characteristic of a specific polypeptide.

10 **Operably linked.** As used herein means that the promoter is positioned to control the initiation of expression of the polypeptide encoded by the structural gene.

15 **Expression.** Expression is the process by which a gene produces a polypeptide. It includes transcription of the gene into messenger RNA (mRNA) and the translation of such mRNA into polypeptide(s).

20 **Substantially Pure.** As used herein "substantially pure" means that the desired purified protein is essentially free from contaminating cellular contaminants which are associated with the desired protein in nature. Contaminating cellular components may include, but are not limited to, phosphatases, exonucleases, endonucleases or undesirable DNA polymerase enzymes.

25 **Primer.** As used herein "primer" refers to a single-stranded oligonucleotide that is extended by covalent bonding of nucleotide monomers during amplification or polymerization of a DNA molecule.

30 **Template.** The term "template" as used herein refers to a double-stranded or single-stranded DNA molecule which is to be amplified, synthesized or sequenced. In the case of a double-stranded DNA molecule, denaturation of its strands to form a first and a second strand is performed before these molecules may be amplified, synthesized or sequenced. A primer, complementary to a portion of a DNA template is hybridized under appropriate conditions and the DNA polymerase of the invention may then synthesize a DNA molecule

complementary to said template or a portion thereof. The newly synthesized DNA molecule, according to the invention, may be equal or shorter in length than the original DNA template. Mismatch incorporation during the synthesis or extension of the newly synthesized DNA molecule may result in one or a number of mismatched base pairs. Thus, the synthesized DNA molecule need not be exactly complementary to the DNA template.

Incorporating. The term "incorporating" as used herein means becoming a part of a DNA molecule or primer.

Amplification. As used herein "amplification" refers to any *in vitro* method for increasing the number of copies of a nucleotide sequence with the use of a DNA polymerase. Nucleic acid amplification results in the incorporation of nucleotides into a DNA molecule or primer thereby forming a new DNA molecule complementary to a DNA template. The formed DNA molecule and its template can be used as templates to synthesize additional DNA molecules. As used herein, one amplification reaction may consist of many rounds of DNA replication. DNA amplification reactions include, for example, polymerase chain reactions (PCR). One PCR reaction may consist of 30 to 100 "cycles" of denaturation and synthesis of a DNA molecule.

Oligonucleotide. "Oligonucleotide" refers to a synthetic or natural molecule comprising a covalently linked sequence of nucleotides which are joined by a phosphodiester bond between the 3' position of the pentose of one nucleotide and the 5' position of the pentose of the adjacent nucleotide.

Nucleotide. As used herein "nucleotide" refers to a base-sugar-phosphate combination. Nucleotides are monomeric units of a nucleic acid sequence (DNA and RNA). The term nucleotide includes deoxyribonucleoside triphosphates such as dATP, dCTP, dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives include, for example, dm, [αS]dATP and 2-deaza-dGTP. The term nucleotide as used herein also refers to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives. Illustrated examples of dideoxyribonucleoside triphosphates include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP. According to the present invention, a "nucleotide" may be unlabeled or detectably labeled by

well known techniques. Detectable labels include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.

5 **Thermostable.** As used herein "thermostable" refers to a DNA polymerase which is resistant to inactivation by heat. DNA polymerases synthesize the formation of a DNA molecule complementary to a single-stranded DNA template by extending a primer in the 5'-to-3' direction. This activity for mesophilic DNA polymerases may be inactivated by heat treatment. For example, T5 DNA polymerase activity is totally inactivated by exposing the enzyme to a
10 temperature of 90°C for 30 seconds. As used herein, a thermostable DNA polymerase activity is more resistant to heat inactivation than a mesophilic DNA polymerase. However, a thermostable DNA polymerase does not mean to refer to an enzyme which is totally resistant to heat inactivation and thus heat treatment may reduce the DNA polymerase activity to some extent. A thermostable DNA
15 polymerase typically will also have a higher optimum temperature than mesophilic DNA polymerases.

Hybridization. The terms "hybridization" and "hybridizing" refers to the pairing of two complementary single-stranded nucleic acid molecules (RNA and/or DNA) to give a double-stranded molecule. As used herein, two nucleic acid
20 molecules may be hybridized, although the base pairing is not completely complementary. Accordingly, mismatched bases do not prevent hybridization of two nucleic acid molecules provided that appropriate conditions, well known in the art, are used.

3'-to-5' Exonuclease Activity. "3'-to-5' exonuclease activity" is an
25 enzymatic activity well known to the art. This activity is often associated with DNA polymerases and is thought to be involved in a DNA replication "editing" or correction mechanism.

5'-to-3' Exonuclease Activity. "5'-to-3' exonuclease activity" is also an
30 enzymatic activity well known in the art. This activity is often associated with DNA polymerases, such as *E. coli* PolI and PolIII.

A "DNA polymerase substantially reduced in 3'-to-5' exonuclease activity" is defined herein as either (1) a mutated DNA polymerase that has about or less than 10%, or preferably about or less than 1%, of the 3'-to-5' exonuclease activity of the corresponding unmutated, wild-type enzyme, or (2) a DNA polymerase having a 3'-to-5' exonuclease specific activity which is less than about 1 unit/mg protein, or preferably about or less than 0.1 units/mg protein. A unit of activity of 3'-to-5' exonuclease is defined as the amount of activity that solubilizes 10 nmoles of substrate ends in 60 min. at 37°C, assayed as described in the "BRL 1989 Catalogue & Reference Guide", page 5, with *HhaI* fragments of *lambda* DNA 3'-end labeled with [³H]dTTP by terminal deoxynucleotidyl transferase (TdT). Protein is measured by the method of Bradford, *Anal. Biochem.* 72:248 (1976). As a means of comparison, natural, wild-type T5-DNAP or T5-DNAP encoded by pTTQ19-T5-2 has a specific activity of about 10 units/mg protein while the DNA polymerase encoded by pTTQ19-T5-2(Exo⁻) (U.S. 5,270,179) has a specific activity of about 0.0001 units/mg protein, or 0.001% of the specific activity of the unmodified enzyme, a 10⁵-fold reduction.

A "DNA polymerase substantially reduced in 5'-to-3' exonuclease activity" is defined herein as either (1) a mutated DNA polymerase that has about or less than 10%, or preferably about or less than 1%, of the 5'-to-3' exonuclease activity of the corresponding unmutated, wild-type enzyme, or (2) a DNA polymerase having 5'-to-3' exonuclease specific activity which is less than about 1 unit/mg protein, or preferably about or less than 0.1 units/mg protein.

Both of these activities, 3'-to-5' exonuclease activity and 5'-to-3' exonuclease activity, can be observed on sequencing gels. Active 5'-to-3' exonuclease activity will produce nonspecific ladders in a sequencing gel by removing nucleotides from growing primers. 3'-to-5' exonuclease activity can be measured by following the degradation of radiolabeled primers in a sequencing gel. Thus, the relative amounts of these activities, e.g. by comparing wild-type and mutant polymerases, can be determined from these characteristics of the sequencing gel.

A. *Cloning and Expression of Thermotoga neapolitana DNA Polymerase*

The *Thermotoga* DNA polymerase of the invention can be isolated from any strain of *Thermotoga* which produces a DNA polymerase having the molecular weight of about 100 kilodaltons. The preferred strain to isolate the gene encoding *Thermotoga* DNA polymerase of the present invention is *Thermotoga neapolitana*. The most preferred *Thermotoga neapolitana* for isolating the DNA polymerase of the invention was isolated from an African continental solfataric spring (Windberger *et al.*, *Arch. Microbiol.* 151:506-512 (1989) and may be obtained from Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ; German Collection of Microorganisms and Cell Culture) Mascheroder Weg 1b D-3300 Braunschweig, Federal Republic of Germany, as Deposit No. 5068.

To clone a gene encoding a *Thermotoga neapolitana* DNA polymerase of the invention, isolated DNA which contains the polymerase gene, obtained from *Thermotoga neapolitana* cells, is used to construct a recombinant DNA library in a vector. Any vector, well known in the art, can be used to clone the wild type or mutant *Thermotoga neapolitana* DNA polymerase of the present invention. However, the vector used must be compatible with the host in which the recombinant DNA library will be transformed.

Prokaryotic vectors for constructing the plasmid library include plasmids such as those capable of replication in *E. coli* such as, for example, pBR322, ColE1, pSC101, pUC-vectors (pUC18, pUC19, etc.: In: *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1982); and Sambrook *et al.*, In: *Molecular Cloning A Laboratory Manual* (2nd ed.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989)). Bacillus plasmids include pC194, pC221, pC217, etc. Such plasmids are disclosed by Glyczan, T. In: *The Molecular Biology Bacilli*, Academic Press, York (1982), 307-329. Suitable *Streptomyces* plasmids include pIJ101 (Kendall *et al.*, *J. Bacteriol* 169:4177-4183 (1987)). *Pseudomonas* plasmids are reviewed by John *et al.*, (*Rad. Insec. Diso.* 8:693-704 (1986)), and

Igaki, (*Jpn. J. Bacteriol.* 33:729-742 (1978)). Broad-host range plasmids or cosmids, such as pCP13 (Darzins and Chakrabarty, *J. Bacteriol.* 159:9-18, 1984) can also be used for the present invention. The preferred vectors for cloning the genes of the present invention are prokaryotic vectors. Preferably, pCP13 and pUC vectors are used to clone the genes of the present invention.

The preferred host for cloning the wild type or mutant DNA polymerase genes of the invention is a prokaryotic host. The most preferred prokaryotic host is *E. coli*. However, the wild type or mutant DNA polymerase genes of the present invention may be cloned in other prokaryotic hosts including, but not limited to, *Escherichia*, *Bacillus*, *Streptomyces*, *Pseudomonas*, *Salmonella*, *Serratia*, and *Proteus*. Bacterial hosts of particular interest include *E. coli* DH10B, which may be obtained from Life Technologies, Inc. (LTI) (Gaithersburg, MD).

Eukaryotic hosts for cloning and expression of the wild type or mutant DNA polymerases of the present invention include yeast, fungi, and mammalian cells. Expression of the desired DNA polymerase in such eukaryotic cells may require the use of eukaryotic regulatory regions which include eukaryotic promoters. Cloning and expressing the wild type or mutant DNA polymerase gene of the invention in eukaryotic cells may be accomplished by well known techniques using well known eukaryotic vector systems.

Once a DNA library has been constructed in a particular vector, an appropriate host is transformed by well known techniques. Transformed colonies are plated at a density of approximately 200-300 colonies per petri dish. Colonies are then screened for the expression of a heat stable DNA polymerase by transferring transformed *E. coli* colonies to nitrocellulose membranes. After the transferred cells are grown on nitrocellulose (approximately 12 hours), the cells are lysed by standard techniques, and the membranes are then treated at 95°C for 5 minutes to inactivate the endogenous *E. coli* enzyme. Other temperatures may be used to inactivate the host polymerases depending on the host used and the temperature stability of the DNA polymerase to be cloned. Stable DNA polymerase activity is then detected by assaying for the presence of DNA

polymerase activity using well known techniques. Sagner *et al.*, *Gene* 97:119-123 (1991), which is hereby incorporated by reference in its entirety. The gene encoding a DNA polymerase of the present invention can be cloned using the procedure described by Sagner *et al.*, *supra*.

5 The recombinant host containing the wild type gene encoding DNA polymerase, *E. coli* DH10B (pUC-Tne), was deposited on September 30, 1994, with the Patent Culture Collection, Northern Regional Research Center, USDA, 1815 North University Street, Peoria, IL 61604 USA as Deposit No. NRRL B-21338.

10 If the Tne DNA polymerase has 3'-to-5' exonuclease activity, this activity may be reduced, substantially reduced, or eliminated by mutating the Tne DNA polymerase gene. Such mutations include point mutations, frame shift mutations, deletions and insertions. Preferably, the region of the gene encoding the 3'-to-5' exonucleated activity is deleted using techniques well known in the art (Sambrook *et al.*, (1989) in: *Molecular Cloning, A Laboratory Manual (2nd Ed.)*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).

15 The 3'-to-5' exonuclease activity can be deleted by creating site specific mutants within the 3'-5' exonuclease domain. *See infra*. In a specific embodiment of the invention Asp³²² of Tne DNA polymerase was changed to Ala³²² to substantially reduce 3'-to-5' exonuclease activity.

20 The 5'-3' exonuclease activity of the Tne DNA polymerase can be reduced or eliminated by mutating the Tne DNA polymerase gene. Such mutations include point mutations, frame shift mutations, deletions, and insertions. Preferably, the region of the gene encoding the 5'-3' exonuclease activity is deleted using techniques well known in the art. In embodiments of this invention, certain conserved amino acids that are associated with the 5'-3' exonuclease activity can be mutated. Examples of these conserved amino acids include Gly¹.
25 In other embodiments, the entire 5'-3' exonuclease domain of e.g., Tne or Tma polymerase can be deleted by proteolytic cleavage or by genetic engineering. For
30 example, a unique *Sph*I restriction site can be used to obtain a clone devoid of

-15-

nucleotides encoding the 219 amino terminal amino acids of Tne DNA polymerase. Examples of such a clone are pTTQTne535FY and pTTQTne5FY.

The DNA polymerase mutants can also be made to render the polymerase non-discriminating against non-natural nucleotides such as dideoxynucleotides.

5 By way of example, one Tne DNA polymerase mutant having this property substitutes a Tyr for Phe at amino acid 67 as numbered in Figure 5. Other changes within the O helix of various polymerases such as other point mutations, deletions, and insertions can also be made.

10 B. *Enhancing Expression of Thermotoga neapolitana DNA Polymerase*

To optimize expression of the wild type or mutant *Thermotoga* DNA polymerases of the present invention, inducible or constitutive promoters are well known and may be used to express high levels of a polymerase structural gene in a recombinant host. Similarly, high copy number vectors, well known in the art,
15 may be used to achieve high levels of expression. Vectors having an inducible high copy number may also be useful to enhance expression of *Thermotoga* DNA polymerase in a recombinant host.

To express the desired structural gene in a prokaryotic cell (such as, *E. coli*, *B. subtilis*, *Pseudomonas*, etc.), it is necessary to operably link the desired structural gene to a functional prokaryotic promoter. However, the natural
20 *Thermotoga neapolitana* promoter may function in prokaryotic hosts allowing expression of the polymerase gene. Thus, the natural *Thermotoga* promoter or other promoters may be used to express the DNA polymerase gene. Such other promoters may be used to enhance expression and may either be constitutive or regulatable (i.e., inducible or derepressible) promoters. Examples of constitutive promoters include the *int* promoter of bacteriophage λ , and the *bla* promoter of the β -lactamase gene of pBR322. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage λ (P_L and P_R), *trp*, *recA*, *lacZ*, *lacI*, *gal*, *trc*, and *tac* promoters of *E. coli*. The *B. subtilis* promoters include α -amylase (Ulmanen *et al.*, *J. Bacteriol* 162:176-182 (1985)) and *Bacillus*
30

bacteriophage promoters (Gryczan, T., In: *The Molecular Biology Of Bacilli*, Academic Press, New York (1982)). *Streptomyces* promoters are described by Ward *et al.*, *Mol. Gen. Genet.* 203:468478 (1986)). Prokaryotic promoters are also reviewed by Glick, *J. Ind. Microbiol.* 1:277-282 (1987); Cenatiemto, Y., *Biochimie* 68:505-516 (1986); and Gottesman, *Ann. Rev. Genet.* 18:415-442 (1984). Expression in a prokaryotic cell also requires the presence of a ribosomal binding site upstream of the gene-encoding sequence. Such ribosomal binding sites are disclosed, for example, by Gold *et al.*, *Ann. Rev. Microbiol.* 35:365404 (1981).

To enhance the expression of Tne DNA polymerase in a eukaryotic cell, well known eukaryotic promoters and hosts may be used. Preferably, however, enhanced expression of Tne DNA polymerase is accomplished in a prokaryotic host. The preferred prokaryotic host for overexpressing this enzyme is *E. coli*.

C. *Isolation and Purification of Thermotoga neapolitana* DNA Polymerase

The enzyme(s) of the present invention (*Thermotoga neapolitana* DNA polymerase, Tne, and mutants thereof) is preferably produced by fermentation of the recombinant host containing and expressing the cloned DNA polymerase gene. However, the wild type and mutant Tne DNA polymerases of the present invention may be isolated from any *Thermotoga* strain which produces the polymerase of the present invention. Fragments of the Tne polymerase are also included in the present invention. Such fragments include proteolytic fragments and fragments having polymerase activity.

Any nutrient that can be assimilated by *Thermotoga neapolitana* or a host containing the cloned Tne DNA polymerase gene may be added to the culture medium. Optimal culture conditions should be selected case by case according to the strain used and the composition of the culture medium. Antibiotics may also be added to the growth media to insure maintenance of vector DNA containing the desired gene to be expressed. Culture conditions for *Thermotoga neapolitana* have, for example, been described by Huber *et al.*, *Arch. Microbiol.* 144:324-333

(1986). Media formulations are also described in DSM or ATCC Catalogs and Sambrook *et al.*, In: *Molecular Cloning, A Laboratory Manual* (2nd ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

5 *Thermotoga neapolitana* and recombinant host cells producing the DNA polymerase of this invention can be separated from liquid culture, for example, by centrifugation. In general, the collected microbial cells are dispersed in a suitable buffer, and then broken down by ultrasonic treatment or by other well known procedures to allow extraction of the enzymes by the buffer solution. After removal of cell debris by ultracentrifugation or centrifugation, the DNA
10 polymerase can be purified by standard protein purification techniques such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis or the like. Assays to detect the presence of the DNA polymerase during purification are well known in the art and can be used during conventional biochemical purification methods to determine the presence of these enzymes.

15 **D. *Uses of Thermotoga neapolitana* DNA polymerase**

The wild type and mutant *Thermotoga neapolitana* DNA polymerases (Tne) of the present invention may be used in well known DNA sequencing, DNA labeling, and DNA amplification reactions. The DNA polymerase mutants devoid of or substantially reduced in 3'→5' exonuclease activity, devoid of or
20 substantially reduced in 5'→3' exonuclease activity, or containing a Phe⁶⁷→Tyr⁶⁷ mutation are especially useful for DNA sequencing, DNA labeling, and DNA amplification reactions. Moreover, Tne polymerase mutants containing two or more of these properties are also especially useful for DNA sequencing, DNA labeling, on DNA amplification reactions. As is well known, sequencing reactions (dideoxy DNA sequencing and cycle DNA sequencing of plasmid DNA) require the use of DNA polymerases. Dideoxy-mediated sequencing involves the use of a chain-termination technique which uses a specific polymer for extension by DNA polymerase, a base-specific chain terminator and the use of polyacrylamide gels to separate the newly synthesized chain-terminated DNA molecules by size so that

at least a part of the nucleotide sequence of the original DNA molecule can be determined. Specifically, a DNA molecule is sequenced by using four separate DNA sequence reactions, each of which contains different base-specific terminators. For example, the first reaction will contain a G-specific terminator, the second reaction will contain a T-specific terminator, the third reaction will contain an A-specific terminator, and a fourth reaction may contain a C-specific terminator. Preferred terminator nucleotides include dideoxynucleoside triphosphates (ddNTPs) such as ddATP, ddTTP, ddGTP, and ddCTP. Analogs of dideoxynucleoside triphosphates may also be used and are well known in the art.

When sequencing a DNA molecule, ddNTPs lack a hydroxyl residue at the 3' position of the deoxyribose base and thus, although they can be incorporated by DNA polymerases into the growing DNA chain, the absence of the 3'-hydroxy residue prevents formation of a phosphodiester bond resulting in termination of extension of the DNA molecule. Thus, when a small amount of one ddNTP is included in a sequencing reaction mixture, there is competition between extension of the chain and base-specific termination resulting in a population of synthesized DNA molecules which are shorter in length than the DNA template to be sequenced. By using four different ddNTPs in four separate enzymatic reactions, populations of the synthesized DNA molecules can be separated by size so that at least a part of the nucleotide sequence of the original DNA molecule can be determined. DNA sequencing by dideoxy-nucleotides is well known and is described by Sambrook *et al.*, In: *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). As will be readily recognized, the Tne DNA polymerase of the present invention may be used in such sequencing reactions

As is well known, detectably labeled nucleotides are typically included in sequencing reactions. Any number of labeled nucleotides can be used in sequencing (or labeling) reactions, including, but not limited to, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels, and enzyme labels. It has been discovered that the wild type and mutant Tne DNA

polymerase of the present invention may be useful for incorporating α S nucleotides ([α S]dATP, [α S]dTTP, [α S]dCTP and [α S]dGTP) during sequencing (or labeling) reactions. For example, [α^{35} S]dATP, a commonly used detectably labeled nucleotide in sequencing reactions, is incorporated three times more efficiently with the Tne DNA polymerase of the present invention, than with Taq DNA polymerase. Thus, the enzyme of the present invention is particularly suited for sequencing or labeling DNA molecules with [α^{35} S]dNTPs.

Polymerase chain reaction (PCR), a well known DNA amplification technique, is a process by which DNA polymerase and deoxyribonucleoside triphosphates are used to amplify a target DNA template. In such PCR reactions, two primers, one complementary to the 3' termini (or near the 3'-termini) of the first strand of the DNA molecule to be amplified, and a second primer complementary to the 3' termini (or near the 3'-termini) of the second strand of the DNA molecule to be amplified, are hybridized to their respective DNA molecules. After hybridization, DNA polymerase, in the presence of deoxyribonucleoside triphosphates, allows the synthesis of a third DNA molecule complementary to the first strand and a fourth DNA molecule complementary to the second strand of the DNA molecule to be amplified. This synthesis results in two double stranded DNA molecules. Such double stranded DNA molecules may then be used as DNA templates for synthesis of additional DNA molecules by providing a DNA polymerase, primers, and deoxyribonucleoside triphosphates. As is well known, the additional synthesis is carried out by "cycling" the original reaction (with excess primers and deoxyribonucleoside triphosphates) allowing multiple denaturing and synthesis steps. Typically, denaturing of double stranded DNA molecules to form single stranded DNA templates is accomplished by high temperatures. The wild type and mutant *Thermotoga* DNA polymerases of the present invention are heat stable DNA polymerases, and thus will survive such thermal cycling during DNA amplification reactions. Thus, the wild type and mutant Tne DNA polymerases of the invention are ideally suited for PCR reactions, particularly where high temperatures are used to denature the DNA molecules during amplification.

E. Kits

The wild type and mutant *Thermotoga neapolitana* (Tne) DNA polymerases of the invention are suited for the preparation of a kit. Kits comprising the wild type or mutant Tne DNA polymerase(s) may be used for detectably labeling DNA molecules, DNA sequencing, or amplifying DNA molecules by well known techniques, depending on the content of the kit. Such kits may comprise a carrying means being compartmentalized to receive in close confinement one or more container means such as vials, test tubes and the like. Each of such container means comprises components or a mixture of components needed to perform DNA sequencing, DNA labeling, or DNA amplification.

A kit for sequencing DNA may comprise a number of container means. A first container means may, for example, comprise a substantially purified sample of Tne DNA polymerase having the molecular weight of about 100 kilodaltons or a mutant thereof. A second container means may comprise one or a number of types of nucleotides needed to synthesize a DNA molecule complementary to DNA template. A third container means may comprise one or a number different types of dideoxynucleotide triphosphates. In addition to the above container means, additional container means may be included in the kit which comprise one or a number of DNA primers.

A kit used for amplifying DNA will comprise, for example, a first container means comprising a substantially pure mutant or wild type Tne DNA polymerase and one or a number of additional container means which comprise a single type of nucleotide or mixtures of nucleotides. Various primers may or may not be included in a kit for amplifying DNA.

When desired, the kit of the present invention may also include container means which comprise detectably labeled nucleotides which may be used during the synthesis or sequencing of a DNA molecule. One of a number of labels may be used to detect such nucleotides. Illustrative labels include, but are not limited to, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.

Having now generally described the invention, the same will be more readily understood through reference to the following Examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

5 **Example 1: Bacterial Strains And Growth Conditions**

Thermotoga neapolitana DSM No. 5068 was grown under anaerobic conditions as described in the DSM catalog (addition of resazurin, Na₂S, and sulfur granules while sparging the media with nitrogen) at 85°C in an oil bath from 12 to 24 hours. The cells were harvested by filtering the broth through Whatman
10 #1 filter paper. The supernatant was collected in an ice bath and then centrifuged in a refrigerated centrifuge at 8,000 rpms for twenty minutes. The cell paste was stored at -70°C prior to total genomic DNA isolation.

E. coli strains were grown in 2X LB broth base (Lennox L broth base: GIBCO/BRL) medium. Transformed cells were incubated in SOC (2% tryptone,
15 0.5% yeast extract, yeast 10 mM NaCl, 2.5 M KCl, 20mM glucose, 10mM MgCl₂, and 10mM MgSO₄ per liter) before plating. When appropriate antibiotic supplements were 20 mg/l tetracycline and 100 mg/l ampicillin. *E. coli* strain DH10B (Lorow *et al.*, *Focus* 12:19-20 (1990)) was used as host strain. Competent DH10B may be obtained from Life Technologies, Inc. (LTI)
20 (Gaithersburg, MD).

Example 2: DNA Isolation

Thermotoga neapolitana chromosomal DNA was isolated from 10⁸ cells by suspending the cells in 2.5 ml TNE (50mM Tris-HCl, pH 8.0, 50mM NaCl, 10mM EDTA) and treated with 1% SDS for 10 minutes at 37°C. DNA
25 was extracted with phenol by gently rocking the lysed cells overnight at 4°C. The next day, the lysed cells were extracted with chloroform:isoamyl alcohol. The resulting chromosomal DNA was further purified by centrifugation in a CsCl

density gradient. Chromosomal DNA isolated from the density gradient was extracted three times with isopropanol and dialyzed overnight against a buffer containing 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA.

Example 3: Construction of Genomic Libraries

5 The chromosomal DNA isolated in Example 2 was used to construct a genomic library in the plasmid pCP13. Briefly, 10 tubes each containing 10 μ g of *Thermotoga neapolitana* chromosomal DNA was digested with 0.01 to 10 units of Sau3AI for 1 hour at 37°C. A portion of the digested DNA was tested in an agarose (1.2%) gel to determine the extent of digestion. Samples with less than 10 50% digestion were pooled, ethanol precipitated and dissolved in TE. 6.5 μ g of partially digested chromosomal DNA was ligated into 1.5 μ g of pCP13 cosmid which had been digested with BamHI restriction endonuclease and dephosphorylated with calf intestinal alkaline phosphatase. Ligation of the partially digested *Thermotoga* DNA and BamHI cleaved pCP13 was carried out 15 with T4 DNA ligase at 22°C for 16 hours. After ligation, about 1 μ g of ligated DNA was packaged using λ -packaging extract (obtained from Life Technologies, Inc., Gaithersburg, MD). DH10B cells (Life Tech. Inc.) were then infected with 100 μ l of the packaged material. The infected cells were plated on tetracycline containing plates. Serial dilutions were made so that approximately 200 to 300 20 tetracycline resistant colonies were obtained per plate.

Example 4: Screening for Clones Expressing Thermotoga neapolitana DNA Polymerase

Identification of the *Thermotoga neapolitana* DNA polymerase gene of the invention was cloned using the method of Sanger *et al.*, *Gene* 97:119-123 (1991) 25 which reference is herein incorporated in its entirety. Briefly, the *E. coli* tetracycline resistant colonies from Example 3 were transferred to nitrocellulose membranes and allowed to grow for 12 hours. The cells were then lysed with the

fumes of chloroform:toluene (1:1) for 20 minutes and dried for 10 minutes at room temperature. The membranes were then treated at 95°C for 5 minutes to inactivate the endogenous *E. coli* enzymes. Surviving DNA polymerase activity was detected by submerging the membranes in 15 ml of polymerase reaction mix

5 (50 mM Tris-HCl (pH 8.8), 1 mM MgCl₂, 3 mM β-mercaptoethanol, 10 μM dCTP, dGTP, dTTP, and 15 μCi of 3,000 Ci/mmol [α^{32} P]dATP) for 30 minutes at 65°C.

Using autoradiography, three colonies were identified that expressed a *Thermotoga neapolitana* DNA polymerase. The cells were grown in liquid

10 culture and the protein extract was made by sonication. The presence of the cloned thermostable polymerase was confirmed by treatment at 90°C followed by measurement of DNA polymerase activity by incorporation of radioactive deoxyribonucleoside triphosphates into acid insoluble DNA. One of the clones, expressing Tne DNA polymerase, contained a plasmid designated pCP13-32 was

15 used for further study.

Example 5: Subcloning of Tne DNA polymerase

Since the pCP13-32 clone expressing the Tne polymerase gene contains about 25 kb of *T. neapolitana* DNA, we attempted to subclone a smaller fragment of the Tne polymerase gene. The molecular weight of the Tne polymerase purified

20 from *E. coli*/pCP13-32 was about 100 kD. Therefore, a 2.5-3.0 kb DNA fragment will be sufficient to code for full-length polymerase. A second round of *Sau*3A partial digestion similar to Example 3 was done using pCP13-32 DNA. In this case, a 3.5 kb region was cut out from the agarose gel, purified by Gene Clean (BIO 101, La Jolla, CA) and ligated into plasmid pSport 1 (Life Technologies, Inc.) which had been linearized with *Bam*HI and dephosphorylated with calf intestinal phosphatase. After ligation, DH10B was transformed and colonies were tested for DNA polymerase activity as described in Example 4. Several clones were identified that expressed Tne DNA polymerase. One of the clones (pSport-Tne) containing about 3 kb insert was further characterized. A restriction

map of the DNA fragment is shown in Fig. 4. Further, a 2.7 Kb *HindIII-SstI* fragment was subcloned into pUC19 to generate pUC19-Tne. *E. coli*/pUC19-Tne also produced Tne DNA polymerase.

The Tne polymerase clone was sequenced by methods known in the art. The nucleotide sequence obtained of the 5' end prior to the start ATG is shown in SEQ ID NO:1. The nucleotide sequence obtained which encodes the Tne polymerase is shown in SEQ ID NO:2. When SEQ ID NO:2 is translated it does not produce the entire amino acid sequence of the Tne polymerase due to frame shift errors in the nucleotide sequence set forth in SEQ ID NO:2. However, an amino acid sequence of the Tne polymerase was obtained by translating all three reading frames of SEQ ID NO:2, comparing these sequences with known polymerase amino acid sequences, and splicing the Tne polymerase sequence together to form the amino acid sequence set forth in SEQ ID NO:3.

Example 6: Purification of Thermotoga neapolitana DNA Polymerase from E. coli

Twelve grams of *E. coli* cells expressing cloned Tne DNA polymerase (DH10B/pSport-Tne) were lysed by sonication (four thirty-second bursts with a medium tip at the setting of nine with a Heat Systems Ultrasonics Inc., model 375 sonicator) in 20 ml of ice cold extraction buffer (50 mM Tris HCl, pH 7.4, 8% glycerol, 5 mM mercaptoethanol, 10 mM NaCl, 1 mM EDTA, 0.5 mM PMSF). The sonicated extract was heated at 80°C for 15 min. and then cooled in ice for 5 min. 50 mM KCl and PEI (0.4%) was added to remove nucleic acids. The extract was centrifuged for clarification. Ammonium sulfate was added at 60%, the pellet was collected by centrifugation and resuspended in 10 ml of column buffer (20 mM Tris-HCl, pH 7.4, 8% glycerol, 5 mM EDTA, 5 mM 2-mercaptoethanol, 10 mM KCl). A Blue-Sepharose (Pharmacia) column, or preferably a Toso heparin (Tosohaas) column, was washed with 7 column volumes of column buffer and eluted with a 15 column volume gradient of buffer A from 10mM to 2 M KCl. Fractions containing polymerase activity were pooled. The

-25-

fractions were dialyzed against 20 volumes of column buffer. The pooled fractions were applied to a Toso650Q column (Tosohaas). The column was washed to baseline OD₂₈₀ and elution effected with a linear 10 column volume gradient of 25 mM Tris, pH 7.4, 8% glycerol, 0.5 mM EDTA, 10 mM KCl, 5 mM β -mercaptoethanol to the same buffer plus 650 mM KCl. Active fractions were pooled.

Example 7: Characterization of Purified Tne DNA Polymerase

1. Determination of the Molecular Weight of Thermotoga neapolitana DNA Polymerase

The molecular weight of 100 kilodaltons was determined by electrophoresis in a 12.5% SDS gel by the method of Laemmli, U.K., *Nature* (Lond.) 227:680-685 (1970). Proteins were detected by staining with Coomassie brilliant blue. A 10 kd protein ladder (Life Technologies, Inc.) was used as standard.

2. Method for Measuring Incorporation of [α^{35} S]-dATP Relative to 3 H-dATP

Incorporation of [α S]dATP was evaluated in a final volume of 500 μ l of reaction mix, which was preincubated at 72°C for five minutes, containing either a [3 H]TTP nucleotide cocktail (100 μ M each TTP, dATP, dCTP, dGTP with [3 H]TTP at 90.3 cpm/pmol), a nucleotide cocktail containing [α S]dATP as the only source of dATP (100 μ M each [α S]dATP, dCTP, dGTP, TTP with [α^{35} S]dATP at 235 cpm/pmol), or a mixed cocktail (50 μ M [α S]dATP, 50 μ M dATP, 100 μ M TTP, 100 μ M dCTP, 100 μ M dGTP with [35 S] dATP at 118 cpm/pmol and [3 H]TTP at 45.2 cpm/pmol). The reaction was initiated by the addition of 0.3 units of *T. neapolitana* DNA polymerase or *T. aquaticus* DNA polymerase. At the times indicated a 25 μ l aliquot was removed and quenched by addition of ice cold EDTA to a final concentration of 83 mM. 20 μ l aliquots of

the quenched reaction samples were spotted onto GF/C filters. Rates of incorporation were compared and expressed as a ratio of *T. neapolitana* to *T. aquaticus*. The incorporation of [α^{35} S]dATP by *T. neapolitana* DNA polymerase was three-fold higher than that of *T. aquaticus* DNA polymerase.

5

Example 8: Reverse Transcriptase Activity

(A)_n:(dT)₁₂₋₁₈ is the synthetic template primer used most frequently to assay for reverse transcriptase activity of DNA polymerases. It is not specific for retroviral-like reverse transcriptase, however, being copied by many prokaryotic and eukaryotic DNA polymerases (Modak and Marcus, *J. Biol. Chem.* 252:11-19 (1977); Gerard *et al.*, *Biochem.* 13:1632-1641 (1974); Spadari and Weissbach, *J. Biol. Chem.* 249:5809-5815 (1974)). (A)_n:(dT)₁₂₋₁₈ is copied particularly well by cellular, replicative DNA polymerases in the presence of Mn⁺⁺, and much less efficiently in the presence of Mg⁺⁺ (Modak and Marcus, *J. Biol. Chem.* 252:11-19 (1977); Gerard *et al.*, *Biochem.* 13:1632-1641 (1974); Spadari and Weissbach, *J. Biol. Chem.* 249:5809-5815 (1974)). In contrast, most cellular, replicative DNA polymerases do not copy the synthetic template primer (C)_n:(dG)₁₂₋₁₈ efficiently in presence of either Mn⁺⁺ or Mg⁺⁺, but retroviral reverse transcriptases do. Therefore, in testing for the reverse transcriptase activity of a DNA polymerase with synthetic template primers, the stringency of the test increases in the following manner from least to most stringent: (A)_n:(dT)₁₂₋₁₈ (Mn⁺⁺) < (A)_n:(dT)₁₂₋₁₈ (Mg⁺⁺) << (C)_n:(dG)₁₂₋₁₈ (Mn⁺⁺) < (C)_n:(dG)₁₂₋₁₈ (Mg⁺⁺).

20

The reverse transcriptase activity of *Thermotoga neapolitana* (Tne) DNA polymerase was compared with *Thermus thermophilus* (Tth) DNA polymerase utilizing both (A)_n:(dT)₁₂₋₁₈ and (C)_n:(dG)₁₂₋₁₈ reaction mixtures. Reaction mixtures with (A)_n:(dT)₂₀ contained 50 mM Tris-HCl (pH 8.4), 100 μ M (A)_n, 100 μ M (dT)₂₀, and either 40 mM KCl, 6 mM MgCl₂, 10 mM dithiothreitol, and 500 μ M [3 H]dTTP (85 cpm/pmole), or 100 mM KCl, 1 mM MnCl₂, and 200 μ M [3 H]dTTP (92 cpm/pmole). Reaction mixtures (50 μ l) with (C)_n:(dG)₁₂₋₁₈ contained 50 mM Tris-HCl (pH 8.4), 60 μ M (C)_n, 24 μ M (dG)₁₂₋₁₈, and either 50

mM KCl, 10 mM MgCl₂, 10 mM dithiothreitol, and 100 μM [³H]dGTP (132 cpm/pmole), or 100 mM KCl, 0.5 mM MnCl₂, and 200 μM [³H]dGTP (107 cpm/pmole). Reaction mixtures also contained either 2.5 units of the Tth DNA polymerase (Perkin-Elmer) or 2.5 units of the Tne DNA polymerase. Incubations were at 45°C for 10 min followed by 75°C for 20 min.

The table shows the results of determining the relative levels of incorporation of Tne and Tth DNA polymerase with (A)_n:(dT)₂₀ and (C)_n:(dG)₁₂₋₁₈ in the presence of Mg⁺⁺ and Mn⁺⁺. Tne DNA polymerase appears to be a better reverse transcriptase than Tth DNA polymerase under reaction conditions more specific for reverse transcriptase, i.e., in the presence of (A)_n:(dT)₂₀ with Mg⁺⁺ and (C)_n:(dG)₁₂₋₁₈ with Mn⁺⁺ or Mg⁺⁺.

DNA Polymerase Activity of Tth and Tne
DNA Polymerase with (A)_n:(dT)₂₀ and (C)_n:(dG)₁₂₋₁₈

Enzyme	DNA Polymerase Activity (pMoles Complementary [³ H]dNTP Incorporated)			
	(A) _n :(dT) ₂₀ Mg ⁺⁺ Mn ⁺⁺		(C) _n :(dG) ₁₂₋₁₈ Mg ⁺⁺ Mn ⁺⁺	
Tne	161.8	188.7	0.6	4.2
Tth	44.8	541.8	0	0.9

Example 9: Construction of *Thermotoga Neapolitana* 3'-to-5' Exonuclease Mutant

The amino acid sequence of portions of the Tne DNA polymerase was compared with other known DNA polymerases such as *E. coli* DNA polymerase I, Taq DNA polymerase, T5 DNA polymerase, and T7 DNA polymerase to localize the regions of 3'-to-5' exonuclease activity, and the dNTP binding domains within the DNA polymerase. We have determined that one of the 3'-to-5' exonuclease domains based on the comparison of the amino acid sequences of

various DNA polymerases (Blanco, L., et al. *Gene* 112: 139-144 (1992); Braithwaite and Ito, *Nucleic Acids Res.* 21: 787-802 (1993)) is as follows:

*

	Tne	317	PSFALDLETSS	327 (SEQ. ID NO. 4)
5	Pol I	350	PVFAFDTETDS	360 (SEQ. ID NO. 5; Braithwaite and Ito, <i>supra</i>)
	T5	133	GPVAFDSETSA	143 (SEQ. ID. NO. 6; Braithwaite and Ito, <i>supra</i>)
10	T7	1	MTVSDIEANA	10 (SEQ. ID. NO. 7; Braithwaite and Ito, <i>supra</i>).

As a first step to make the Tne DNA polymerase devoid of 3'-5' exonuclease activity, a 2kb *Sph* fragment from pSport-Tne was cloned into M13mp19 (LTI, Gaithersburg, MD). The recombinant clone was selected in *E. coli* DH5 α F'IQ (LTI, Gaithersburg, MD). One of the clones with the proper insert was used to isolate uracilated single-stranded DNA by infecting *E. coli* CJ236 (Biorad, California) with the phage particle obtained from *E. coli* DH5 α F'IQ. An oligonucleotide, GA CGT TTC AAG CGC TAG GGC AAA AGA (SEQ ID NO. 8) was used to perform site directed mutagenesis. This site-directed mutagenesis converted Asp³²² (indicated as * above) to Ala³²². An *Eco*47III restriction site was created as part of this mutagenesis to facilitate screening of the mutant following mutagenesis. The mutagenesis was performed using a protocol as described in the Biorad manual (1987) except T7 DNA polymerase was used instead of T4 DNA polymerase (USB, Cleveland, OH). The mutant clones were screened for the *Eco*47III restriction site that was created in the mutagenic oligonucleotide. One of the mutants having the created *Eco*47III restriction site was used for further study.

To incorporate the 3'-to-5' exonuclease mutation in an expression vector, the mutant phage was digested with *Sph*I and *Hind*III. A 2 kb fragment containing the mutation was isolated. This fragment was cloned in pUC-Tne to replace the wild type fragment. See Figure 6A. The desired clone, pUC-Tne

RECTIFIED SHEET (RULE 91)

(3'-5'), was isolated. The presence of the mutant sequence was confirmed by the presence of the unique *Eco47III* site. The plasmid was then digested with *SsrI* and *HindIII*. The entire mutant polymerase gene (2.6 kb) was purified and cloned into *SsrI* and *HindIII* digested pTrc99 expression vector (Pharmacia, Sweden). The clones were selected in DH10B (LTI, Gaithersburg, MD). The resulting plasmid was designated pTrcTne35. See Figure 6B. This clone produced active heat stable DNA polymerase.

Example 10: Phenylalanine to Tyrosine Mutant

As discussed *supra*, the polymerase active site including the dNTP binding domain is usually present at the carboxyl terminal region of the polymerase. The preliminary and partial sequence of the Tne polymerase gene suggests that the amino acids that presumably contact and interact with the dNTPs are present within the 694 bases starting at the internal *BamHI* site. See Figure 4. This conclusion is based on homology with a prototype polymerase *E. coli* polymerase I. See Polisky et al., *J. Biol. Chem.* 265:14579-14591 (1990). The sequence of the carboxyl terminal portion of the polymerase gene is shown in Figure 5. Based upon this sequence, it is possible to compare the amino acid sequence within the O-helix for various polymerases:

			*	
Tne	63	KMVNFSIIYG	72	(SEQ ID NO. 9)
Pol I	758	KAINFGIIYG	767	(SEQ ID NO. 10)
T5	566	KAITFGIIYG	575	(SEQ ID NO. 11)
T7	522	KTFIYGFLYG	531	(SEQ ID NO. 12)
Taq	663	KTINFGVLYG	672	(SEQ ID NO. 13)

It was shown that by replacing the phenylalanine residue of Taq DNA polymerases, (indicated as * above) the polymerase becomes non-discriminating against non-natural nucleotides such as dideoxynucleotides. See application Serial No. 08/525,087 entitled "Mutant DNA Polymerases and Use Thereof" of Deb K. Chatterjee, filed September 8, 1995, specifically incorporated herein by reference.

The mutation was based on the assumption that T7 DNA polymerase contains a tyrosine residue in place of the phenylalanine, and T7 DNA polymerase is non-discriminating against dideoxynucleotides. The corresponding residue, Phe⁷⁰² of *E. coli* PolI is an amino acid that directly interacts with nucleotides. (Joyce and Steitz, *Ann. Rev. Biochem.* 63:777-822 (1994); Astake, M.J., *J. Biol. Chem.* 270:1945-1954 (1995)). We prepared a similar mutant of Tne DNA polymerases.

In order to change Phe⁶⁷ of the Tne polymerase to a Tyr⁶⁷ as numbered in Figure 5, we performed a site-directed mutagenesis using the oligonucleotide GTA TAT TAT AGA GTA GTT AAC CAT CTT TCC A. (SEQ ID NO. 14) As part of this oligonucleotide directed mutagenesis, a *HpaI* restriction site was created in order to screen mutants easily. The same uracilated single-stranded DNA and mutagenesis procedure described in Example 9 were used for this mutagenesis. Following mutagenesis, the mutants were screened for the *HpaI* site. Mutants with the desired *HpaI* site were used for further study.

The Phe⁶⁷ to Tyr⁶⁷ mutation was incorporated into pUC-Tne by replacing the wild type *SphI*-*HindIII* fragment with the mutant fragment obtained from the mutant phage DNA. The presence of the desired clone, pUC-TneFY, was confirmed by the presence of the unique *HpaI* site, see Figure 6A. The entire mutant polymerase gene was subcloned into pTrc99 as an *SstI*-*HindIII* as described above in DH10B. The resulting plasmid was designated pTrcTneFY. (Figure 6B) The clone produced active heat stable polymerase.

Example 11: 3'-to-5' Exonuclease and Phe⁶⁷→Tyr⁶⁷ Double Mutants

In order to introduce the 3'-5' exonuclease mutation and the Phe⁶⁷→Tyr⁶⁷ mutation in the same expression vector, pTrc99, it was necessary to first reconstitute both mutations in the pUC-Tne clone. See Figure 7. Both the pUC-Tne (3'-5') and the pUC-TneFY were digested with *Bam*HI. The digested pUC-Tne (3'-5') was dephosphorylated to avoid recirculation in the following ligations. The resulting fragments were purified on a 1% agarose gel. The largest *Bam*HI fragment (4.4 kb) was purified from pUC-Tne (3'-5') digested DNA and

the smallest *Bam*HI fragment (0.8 kb) containing the Phe⁶⁷→Tyr⁶⁷ mutation was purified and ligated to generate pUC-Tne35FY. The proper orientation and the presence of both mutations in the same plasmid was confirmed by *Eco*47III, *Hpa*I, and *Sph*I-*Hind*III restriction digests. See Figure 7.

5 The entire polymerase containing both mutations was subcloned as a *Sst*I-*Hind*III fragment in pTrc99 to generate pTrcTne35FY in DH10B. The clone produced active heat stable polymerase.

**Example 12: 3'-to-5' Exonuclease, 5'-to-3' Exonuclease, and
Phe⁶⁷→Tyr⁶⁷ Triple Mutants**

10 In most of the known polymerases, the 5'-to-3' exonuclease activity is present at the amino terminal region of the polymerase (Ollis, D.L., *et al.*, *Nature* 313, 762-766, 1985; Freemont, P.S., *et al.*, *Proteins* 1, 66-73, 1986; Joyce, C.M., *Curr. Opin. Struct. Biol.* 1, 123-129, 1991). There are some conserved amino acids that are implicated to be responsible for 5'-to-3' exonuclease activity
15 (Gutman and Minton, *Nucl. Acids Res.* 21, 4406-4407, 1993). *See supra*. It is known that 5'-to-3' exonuclease domain is dispensable. The best known example is the Klenow fragment of *E. coli* Pol I. The Klenow fragment is a natural proteolytic fragment devoid of 5'-to-3' exonuclease activity (Joyce, C.M., *et al.*, *J. Biol. Chem.* 257, 1958-1964, 1990). In order to generate an equivalent mutant
20 for Tne DNA polymerase devoid of 5'-to-3' exonuclease activity we exploited the presence of a unique *Sph*I site present 680 bases from the *Sst*I site. pUC-Tne35FY was digested with *Hind*III, filled-in with Klenow fragment to generate a blunt-end, and digested with *Sph*I. The 1.9 kb fragment was cloned into an expression vector pTTQ19 (Stark, M.J.R., *Gene* 51, 255-267, 1987) at the
25 *Sph*I-*Sma*I sites and was introduced into DH10B. This cloning strategy generated an in-frame polymerase clone with an initiation codon for methionine from the vector. The resulting clone is devoid of 219 amino terminal amino acids of Tne DNA polymerase. This clone is designated as pTTQTne535FY. The clone produced active heat stable polymerase. No exonuclease activity could be

detected in the mutant polymerase as evidenced by lack of primer (labeled with radioisotope) degradation in the sequencing reaction. This particular mutant polymerase is highly suitable for DNA sequencing.

Example 13: 5'-to-3' Exonuclease Deletion and Phe⁶⁷→Tyr⁶⁷

Substitution Mutant

5

10

15

20

25

In order to generate the 5'-3' exonuclease deletion mutant of the Tne DNA polymerase Phe⁶⁷→Tyr⁶⁷ mutant, the 1.8 kb *SphI-SpeI* fragment of pTTQTne35FY was replaced with the identical fragment of pUC-Tne FY. See Fig. 8. A resulting clone, pTTQTne5FY, produced active heat stable DNA polymerase. As measured by the rate of degradation of a labeled primer, this mutant has a modulated, low but detectable, 3' ~ 5' exonuclease activity compared to wild type Tne DNA polymerase. M13 sequencing primer, obtainable from LTI, Gaithersburg, MD, was labeled at the 5' end with [³²P] ATP and T4 kinase, also obtainable from LTI, Gaithersburg, MD, as described by the manufacturer. The reaction mixtures contained 20 units of either wild-type or mutant Tne DNA polymerase, 0.25 pmol of labeled primer, 20 mM tricine, pH 8.7, 85 mM potassium acetate, 1.2 mM magnesium acetate, and 8% glycerol. Incubation was carried out at 70°C. At various time points, 10 ml aliquots were removed to 5 ml cycle sequencing stop solution and were resolved in a 6 % polyacrylamide sequencing gel followed by autoradiography. While the wild-type polymerase degraded the primer in 5 to 15 minutes, it took the mutant polymerase more than 60 minutes for the same amount of degradation of the primer. Preliminary results suggest that this mutant polymerase is able to amplify more than 12 kb of genomic DNA when used in conjunction with Taq DNA polymerase. Thus, the mutant polymerase is suitable for large fragment PCR.

Example 14: Purification of the Mutant Polymerases

The purification of the mutant polymerases was done essentially as described in U.S. Patent Application Serial No. 08/370,190, filed January 9, 1995, entitled "Cloned DNA Polymerases for *Thermotoga neapolitana*," and as in
5 Example 6, *supra*, with minor modifications. Specifically, 5 to 10 grams of cells expressing cloned mutant Tne DNA polymerase were lysed by sonication with a Heat Systems Ultrasonic, Inc. Model 375 machine in a sonication buffer comprising 50 mM Tris-HCl, pH 7.4; 8% glycerol; 5 mM 2-mercaptoethanol, 10 mM NaCl, 1 mM EDTA, and 0.5 mM PMSF. The sonication sample was heated
10 at 75°C for 15 minutes. Following heat treatment, 200 mM NaCl and 0.4% PEI was added to remove nucleic acids. The extract was centrifuged for clarification. Ammonium sulfate was added to 48%, the pellet was resuspended in a column buffer consisting of 25 mM Tris-HCl, pH 7.4; 8% glycerol; 0.5% EDTA; 5 mM 2-mercaptoethanol; 10 mM KCl and loaded on a Heparin agarose column. The
15 column was washed with 10 column volumes using the loading buffer and eluted with a 10 column volume buffer gradient from 10 mM to 1 M KCl. Fractions containing polymerase activity were pooled and dialyzed in column buffer as above with the pH adjusted to 7.8. The dialyzed pool of fractions were loaded onto a mono Q column. The column was washed and eluted as described above
20 for the Heparin column. The active fractions are pooled and a unit assay was performed.

The unit assay reaction mixture contained 25 mM TAPS pH 9.3, 2 mM MgCl₂, 50 mM KCl, 1 mM DTT, 0.2 mM dNTPs, 500 µg/ml DNase I treated salmon sperm DNA, 21 mCi/ml [α P³²] dCTP and various amounts of polymerase
25 in a final volume of 50 µl. After 10 minutes incubation at 70°C, 10 µl of 0.5 M EDTA was added to the tube. TCA precipitable counts were measured in GF/C filters using 40 µl of the reaction mixture.

Example 15: DNA Sequencing with the Mutant Polymerases

Cycle sequencing reactions using P^{32} end-labeled primers were prepared using wild-type Tne DNA polymerase and each of the three mutants, TneFY, Tne35FY, and Tne535FY. All four of the polymerases produced sequencing ladders. The TneFY mutant gave only a 9 base sequencing ladder when the Taq cycle sequencing reaction conditions were used. Diluting the dideoxynucleotides by a factor of 100 extended the ladder to about 200 bases. The F-Y mutation in the Tne FT polymerase therefore allowed dideoxynucleotides to be incorporated at a much higher frequency than for wild-type polymerase. The Tne35FY mutant demonstrated a similar ability to incorporate dideoxynucleotides. In this case, the sequence extended to beyond 400 bases and the excess P^{32} end-labeled M13/pUC forward 23-Base sequencing primer band remained at the 23-base position in the ladder. The persistence of the 23-base primer band confirmed that the 3' - 5' exonuclease activity had been significantly reduced. The Tne535FY mutant performed similarly to the Tne35FY mutant except that the signal intensity increased by at least fivefold. The background was very low and relative band intensities were extremely even, showing no patterns of sequence-dependent intensity variation.

- 35 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: LIFE TECHNOLOGIES, INC.
- (ii) TITLE OF INVENTION: Cloned DNA Polymerases from *Thermotoga Neapolitana* and Mutants Thereof
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX
 - (B) STREET: 1100 New York Avenue, N.W.
 - (C) CITY: Washington
 - (D) STATE: DC
 - (E) COUNTRY: USA
 - (F) ZIP: 20005
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: TO BE ASSIGNED
 - (B) FILING DATE: 02-OCT-1995
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/316,423
 - (B) FILING DATE: 30-SEP-1994
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/370,190
 - (B) FILING DATE: 09-JAN-1995
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Esmond, Robert W.
 - (B) REGISTRATION NUMBER: 32,893
 - (C) REFERENCE/DOCKET NUMBER: 0942.280PC02
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 202-371-2600
 - (B) TELEFAX: 202-371-2540

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:

- 36 -

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: both
- (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGCTCACGG GGGATGCAGG AAA

23

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1310 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: both
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGGCGAGAC TATTTCTCTT TGATGGCACA GCCCTGGCCT ACAGGGCATA TTACGCCCTC	60
GACAGATCCC TTTCCACATC CACAGGAATT CCAACGAACG CCGTCTATGG CGTTGCCAGG	120
ATGCTCGTTA AATTCATTAA GGAACACATT ATACCCGAAA AGGACTACGC GGCTGTGGCC	180
TTGACAAGA AGGCAGCGAC GTTCAGACAC AAACCTGCTG TAAGCGACAA GGCGCAAAGG	240
CCAAAGACGC CGGCTCTTCT AGTTCAGCAG CTACCTTACA TCAAGCGGCT GATAGAAGCT	300
CTTGGTTTCA AAGTGCTGGA GCTGGAAGGG TACGAAGCAG ACGATATCAT CGCCACGCTT	360
GCAGCAAAGG GCTGCACGTT TTTTGATGAG ATTTTCATAA TAACCGGTGA CAAGGATATG	420
CTTCAACTTG TAAACGAGAA GATAAAGGTC TGGAGAATCG TCAAGGGGAT ATCGGATCTT	480
GAGCTTTACG ATTCGAAAAA GGTGAAAGAA AGATACGGTG TGGAACCACA TCAGATACCG	540
GATCTTCTAG CACTGACGGG AGACGACATA GACAACATTC CCGGTGTAAC GGGAAATAGGT	600
GAAAAGACCG CTGTACAGCT TCTCGGCAAG TATAGAAATC TTGAATACAT TCTGGAGCAT	660
GCCCGTGAAC TCCCCAGAG AGTGAGAAAG GCTCTCTTGA GAGACAGGGA AGTTGCCATC	720
CTCAGTAAAA AACTTGCAAC TCTGGTGACG AACGCACCTG TTGAAGTGGA CTGGGAAGAG	780

- 37 -

ATGAAATACA GAGGATACGA CAAGAGAAAA CTACTTCCGA TATTGAAAGA ACTGGAGTTT	840
GCTTCCATCA TGAAGGAACT TCAACTGTAC GAAGAAGCAG AACCCACCGG ATACGAAATC	900
GTGAAGGATC ATAAGACCTT CGAAGATCTC ATCGAAAAGC TGAAGGAGGT TCCATCTTTT	960
GCCCTGGACC TTGAAACGTC CTCCTTGGAC CCGTTCAACT GTGAGATAGT CGGCATCTCC	1020
GTGTCGTTCA AACCGAAAAC AGCTTATTAC ATTCCACTTC ATCAGAGAAA CGCCCACAAT	1080
CTTGATGAAA CACTGGTGCT GTCGAAGTTG AAAGAGATCC TCGAAGACCC GTCTTCGAAG	1140
ATTGTGGGTC AGAACCTGAA GTACGACTAC AAGGTTCTTA TGGTAAAGGG TATATCGCCA	1200
GTTTATCCGC ATTTTGACAC GATGATAGCT GCATATTTGC TGGAGCCAAA CGAGAAAAAA	1260
TTCAATCTCG AAGATCTGTC TTTGAAATTT CTCGGATACA AAATGACGTC	1310

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 436 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Ala	Arg	Leu	Phe	Leu	Phe	Asp	Gly	Thr	Ala	Leu	Ala	Tyr	Arg	Ala	
1				5					10					15		
Tyr	Tyr	Ala	Leu	Asp	Arg	Ser	Leu	Ser	Thr	Ser	Thr	Gly	Ile	Pro	Thr	
			20					25					30			
Asn	Ala	Val	Tyr	Gly	Val	Ala	Arg	Met	Leu	Val	Lys	Phe	Ile	Lys	Glu	
		35					40					45				
His	Ile	Ile	Pro	Glu	Lys	Asp	Tyr	Ala	Ala	Val	Ala	Phe	Asp	Lys	Lys	
		50				55					60					
Ala	Ala	Thr	Phe	Arg	His	Lys	Leu	Leu	Val	Ser	Asp	Lys	Ala	Gln	Arg	
		65			70					75				80		
Pro	Lys	Thr	Pro	Ala	Leu	Leu	Val	Gln	Gln	Leu	Pro	Tyr	Ile	Lys	Arg	
			85					90					95			
Leu	Ile	Glu	Ala	Leu	Gly	Phe	Lys	Val	Leu	Glu	Leu	Glu	Gly	Tyr	Glu	
		100					105						110			

- 38 -

Ala Asp Asp Ile Ile Ala Thr Leu Ala Ala Lys Gly Cys Thr Phe Phe
 115 120 125
 Asp Glu Ile Phe Ile Ile Thr Gly Asp Lys Asp Met Leu Gln Leu Val
 130 135 140
 Asn Glu Lys Ile Lys Val Trp Arg Ile Val Lys Gly Ile Ser Asp Leu
 145 150 155 160
 Glu Leu Tyr Asp Ser Lys Lys Val Lys Glu Arg Tyr Gly Val Glu Pro
 165 170 175
 His Gln Ile Pro Asp Leu Leu Ala Leu Thr Gly Asp Asp Ile Asp Asn
 180 185 190
 Ile Pro Gly Val Thr Gly Ile Gly Glu Lys Thr Ala Val Gln Leu Leu
 195 200 205
 Gly Lys Tyr Arg Asn Leu Glu Tyr Ile Leu Glu His Ala Arg Glu Leu
 210 215 220
 Pro Gln Arg Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Val Ala Ile
 225 230 235 240
 Leu Ser Lys Lys Leu Ala Thr Leu Val Thr Asn Ala Pro Val Glu Val
 245 250 255
 Asp Trp Glu Glu Met Lys Tyr Arg Gly Tyr Asp Lys Arg Lys Leu Leu
 260 265 270
 Pro Ile Leu Lys Glu Leu Glu Phe Ala Ser Ile Met Lys Glu Leu Gln
 275 280 285
 Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu Ile Val Lys Asp His
 290 295 300
 Lys Thr Phe Glu Asp Leu Ile Glu Lys Leu Lys Glu Val Pro Ser Phe
 305 310 315 320
 Ala Leu Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asn Cys Glu Ile
 325 330 335
 Val Gly Ile Ser Val Ser Phe Lys Pro Lys Thr Ala Tyr Tyr Ile Pro
 340 345 350
 Leu His His Arg Asn Ala His Asn Leu Asp Glu Thr Leu Val Leu Ser
 355 360 365
 Lys Leu Lys Glu Ile Leu Glu Asp Pro Ser Ser Lys Ile Val Gly Gln
 370 375 380
 Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val Lys Gly Ile Ser Pro
 385 390 395 400

- 39 -

Val Tyr Pro His Phe Asp Thr Met Ile Ala Ala Tyr Leu Leu Glu Pro
405 410 415

Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser Leu Lys Phe Leu Gly
420 425 430

Tyr Lys Met Thr
435

What Is Claimed Is:

1. A substantially pure *Thermotoga neapolitana* (Tne) DNA polymerase having a molecular weight of about 100 kilodaltons, or fragments thereof.
5
2. The DNA polymerase of claim 1, which is isolated from *Thermotoga neapolitana*.
3. The DNA polymerase of claim 2, which is isolated from *Thermotoga neapolitana* DSM 5068.
4. An isolated DNA molecule comprising a gene encoding a Tne DNA polymerase having a molecular weight of about 100 kilodaltons.
10
5. An isolated DNA molecule of claim 4, wherein the gene is modified to reduce 3'-5' exo activity.
6. The isolated DNA molecule of claim 4, wherein the promoter of said gene is an inducible promoter.
15
7. The isolated DNA molecule of claim 6, wherein said inducible promoter is selected from the group consisting of a λ -P_L promoter, a *tac* promoter, a *trp* promoter, and a *trc* promoter.
8. A recombinant host comprising a gene encoding Tne DNA polymerase having a molecular weight of 100 kilodaltons.
20
9. The recombinant host of claim 8, wherein said gene is obtained from *Thermotoga neapolitana*.

10. The recombinant host of claim 9, wherein said gene is obtained from *Thermotoga neapolitana* DSM 5068.
11. The recombinant host of claim 8, wherein said host is prokaryotic.
12. The recombinant host of claim 11, wherein said host is *E. coli*.
- 5 13. A method of producing a Tne DNA polymerase having a molecular weight of about 100 kilodaltons, said method comprising:
- (a) culturing a cellular host comprising a gene encoding said DNA polymerase;
 - (b) expressing said gene; and
 - 10 (c) isolating said DNA polymerase from said host.
14. The method of claim 13, wherein said host is a eukaryotic host.
15. The method of claim 13, wherein said host is a prokaryotic host.
16. The method of claim 15, wherein said prokaryotic host is *E. coli*.
- 15 17. A method of synthesizing a double-stranded DNA molecule comprising:
- (a) hybridizing a primer to a first DNA molecule; and
 - (b) incubating said DNA molecule of step (a) in the presence of one or more deoxyribonucleoside triphosphates and Tne DNA polymerase having a molecular weight of about 100 kilodaltons, under conditions sufficient to synthesize a second DNA molecule complementary to all or a portion of said first DNA molecule.
- 20 18. The method of claim 17, wherein said DNA polymerase is isolated from *Thermotoga neapolitana*.

19. The method of claim 18, wherein said DNA polymerase is isolated from *Thermotoga neapolitana*. DSM 5068.

20. The method of claim 17, wherein said DNA polymerase is isolated from a recombinant host expressing a gene encoding said DNA polymerase.

5 21. The method of claim 20, wherein said host is a eukaryotic host.

22. The method of claim 20, wherein said host is a prokaryotic host.

23. The method of claim 22, wherein said prokaryotic host is *E. coli*.

10 24. The method of claim 17, wherein said deoxyribonucleoside triphosphates are selected from the group consisting of dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, dUTP, ddATP, ddCTP, ddGTP, ddITP, ddTTP, [α S]dATP, [α S]dTTP, [α S]dGTP, and [α S]dCTP.

25. The method of claim 24, wherein one or more of said deoxyribonucleoside triphosphates are detectably labeled.

15 26. The method of claim 25, wherein said detectable label is selected from the group consisting of a radioactive isotope, a fluorescent label, a chemiluminescent label, a bioluminescent label, and an enzyme label.

20 27. A method of sequencing a DNA molecule, comprising:
(a) hybridizing a primer to a first DNA molecule;
(b) contacting said DNA molecule of step (a) with deoxyribonucleoside triphosphates, The DNA polymerase having a molecular weight of about 100 kilodaltons, and a terminator nucleotide;

(c) incubating the mixture of step (b) under conditions sufficient to synthesize a random population of DNA molecules complementary to said first DNA molecule, wherein said synthesized DNA molecules are shorter in length than said first DNA molecule and wherein said synthesized DNA molecules comprise a terminator nucleotide at their 5' termini; and (d) separating said synthesized DNA molecules by size so that at least a part of the nucleotide sequence of said first DNA molecule can be determined.

28. The method of claim 27, wherein said terminator nucleotide is ddTTP.

29. The method of claim 27, wherein said terminator nucleotide is ddATP.

30. The method of claim 27, wherein said terminator nucleotide is ddGTP.

31. The method of claim 27, wherein said terminator nucleotide is ddCTP.

32. The method of claim 27, wherein said DNA polymerase is isolated from *Thermotoga neapolitana*.

33. The method of claim 32, wherein said DNA polymerase is isolated from *Thermotoga neapolitana* DSM 5068.

34. The method of claim 27, wherein said DNA polymerase is isolated from a recombinant host expressing a gene encoding said DNA polymerase.

35. The method of claim 27, wherein one or more of said deoxyribonucleoside triphosphates is detectably labeled.

36. The method of claim 35, wherein said labeled deoxyribonucleoside triphosphate is [$\alpha^{32}\text{S}$]dATP.

5 37. A method for amplifying a double stranded DNA molecule, comprising:

(a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3'-termini of the first strand of said DNA molecule and said second primer is complementary to a sequence at
10 or near the 3'-termini of the second strand of said DNA molecule;

(b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of The DNA polymerase having a molecular weight of about 100 kilodaltons, under conditions such that a third DNA molecule complementary to said first strand and a fourth DNA molecule complementary to said second strand are synthesized;
15

(c) denaturing said first and third strand, and said second and fourth strands with heat; and (d) repeating steps (a) to (c) one or more times.

38. The method of claim 37, wherein said DNA polymerase is isolated from *Thermotoga neapolitana*.

20 39. The method of claim 38, wherein said DNA polymerase is isolated from *Thermotoga neapolitana* DSM 5068.

40. The method of claim 37, wherein said DNA polymerase is isolated from a recombinant host expressing a gene encoding said DNA Polymerase.

41. A kit for sequencing a DNA molecule, comprising:

(a) a first container means comprising a Tne DNA polymerase having a molecular weight of about 100 kilodaltons;

(b) a second container means comprising one or more dideoxynucleoside triphosphates; and

5 (c) a third container means comprising one or more deoxyribonucleoside triphosphates.

42. The kit of claim 41, wherein said DNA polymerase is isolated from *Thermotoga neapolitana*.

10 43. The kit of claim 42, wherein said DNA polymerase is isolated from *Thermotoga neapolitana* DSM 5068.

44. The kit of claim 41, wherein said DNA polymerase is isolated from a recombinant host expressing a gene encoding said DNA polymerase.

45. A kit for amplifying a DNA molecule, comprising:

15 (a) a first container means comprising a Tne DNA polymerase having a molecular weight of about 100 kilodaltons; and

(b) a second container means comprising one or more deoxyribonucleoside triphosphates.

46. The kit of claim 45, wherein said DNA polymerase is isolated from *Thermotoga neapolitana*.

20 47. The kit of claim 46, wherein said DNA polymerase is isolated from *Thermotoga neapolitana* DSM 5068.

48. The kit of claim 45, wherein said DNA polymerase is isolated from a recombinant host expressing a gene encoding said DNA polymerase.

5 49. A mutant *Thermotoga neapolitana* DNA polymerase having at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'-5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'-3' exonuclease activity of said DNA polymerase; and (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides, or fragments thereof.

50. The mutant *Thermotoga neapolitana* DNA polymerase as claimed in claim 49, wherein said third mutation is a Phe⁶⁷-Tyr⁶⁷ substitution.

10 51. The mutant *Thermotoga neapolitana* DNA polymerase as claimed in claim 49, wherein said first mutant is a Asp³²³-Ala³²² substitution.

52. The mutant *Thermotoga neapolitana* DNA polymerase as claimed in claim 49, wherein said mutant polymerase comprises both a Phe⁶⁷ - Tyr⁶⁷ substitution and a Asp³²² - Ala³²² substitution.

15 53. The mutant *Thermotoga neapolitana* DNA polymerase as claimed in claim 49, wherein said mutant polymerase is devoid of the N- terminal 5'- 3' exonuclease domain.

20 54. The mutant *Thermotoga neapolitana* DNA polymerase as claimed in claim 53, wherein said mutant polymerase is devoid of the 219 N-terminal amino acids of *Thermotoga neapolitana* DNA polymerase.

25 55. An isolated DNA molecule comprising a DNA sequence encoding a mutant *Thermotoga neapolitana* DNA polymerase having at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'-5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'-3' exonuclease activity of said

DNA polymerase; and (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides, or fragments thereof.

5 56. The isolated DNA molecule as claimed in claim 55, wherein said DNA molecule is selected from the group consisting of pTrcTne35, pTrcTneFY, pTrcTne35FY, and pTTQTne535FY.

57. The isolated DNA molecule as claimed in claim 55, wherein said DNA molecule further comprises expression control elements.

10 58. The isolated DNA molecule as claimed in claim 57, wherein said expression control elements comprise an inducible promoter selected from the group consisting of λP_L promoter, a tac promoter, a trp promoter, and a trc promoter.

15 59. A recombinant host comprising a DNA sequence encoding a mutant *Thermotoga neapolitana* DNA polymerase having at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'-5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'-3' exonuclease activity of said DNA polymerase; and (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against
20 dideoxynucleotides, or fragments thereof.

60. A method of producing a Tne DNA polymerase, said method comprising:

25 (a) culturing a cellular host comprising a gene encoding a mutant *Thermotoga neapolitana* DNA polymerase having at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'-5' exonuclease activity of said DNA polymerase; (2) a second

mutation that substantially reduces or eliminates 5'-3' exonuclease activity of said DNA polymerase; and (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides, or fragments of said mutant *Thermotoga neapolitana* DNA polymerase;

(b) expressing said gene; and

(c) isolating said mutant *Thermotoga neapolitana* DNA polymerase from said host.

61. The method of producing a *Thermotoga neapolitana* DNA polymerase as claimed in claim 60, wherein said host is *E. coli*.

62. A method of synthesizing a double-stranded DNA molecule, comprising:

(a) hybridizing a primer to a first DNA molecule; and

(b) incubating said DNA molecule of step (a) in the presence of one or more deoxyribonucleoside triphosphates and a mutant *Thermotoga neapolitana* DNA polymerase under conditions sufficient to synthesize a second DNA molecule complementary to all or a portion of said first DNA molecules; wherein:

said mutant *Thermotoga neapolitana* DNA polymerase has at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'-5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'-3' exonuclease activity of said DNA polymerase; and (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides, or fragments thereof.

63. The method of synthesizing a double-stranded DNA molecule as claimed in claim 62, wherein said deoxyribonucleoside triphosphates are selected from the group consisting of: dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP,

dUTP, ddATP, ddCTP, ddGTP, ddITP, ddTTP, [α S]dATP, [α S]dTTP, [α S]dGTP, and [α S]dCTP.

5 64. The method of synthesizing a double-stranded DNA molecule as claimed in claim 63, wherein one or more of said deoxyribonucleoside triphosphates are detectably labelled.

65. The method of synthesizing a double-stranded DNA molecule as claimed in claim 64, wherein said label is selected from the group consisting of a radioactive isotope, a fluorescent label, a chemiluminescent label, a bioluminescent label, and an enzyme label.

10 66. A method of sequencing a DNA molecule, comprising:
(a) hybridizing a primer to a first DNA molecule;
(b) contacting said DNA molecule of step (a) with deoxyribonucleoside triphosphates, a mutant *Thermotoga neapolitana* DNA polymerase, and a terminator nucleotide;

15 (c) incubating the mixture of step (b) under conditions sufficient to synthesize a random population of DNA molecules complementary to said first DNA molecule;

20 wherein said synthesized DNA molecules are shorter in length than said first DNA molecule and wherein said synthesized DNA molecules comprise a terminator nucleotide at their 5' termini; and

(d) separating said synthesized DNA molecules by size so that at least a part of the nucleotide sequence of said first DNA molecule can be determined.

25 wherein said mutant *Thermotoga neapolitana* DNA polymerase has at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'-5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'-3' exonuclease activity of said DNA polymerase; and (3) a third mutation in the O

-50-

helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides, or fragments thereof.

67. The method sequencing a DNA molecule as claimed in claim 66, wherein said terminator nucleotide is selected from the group consisting of ddTTP, ddATP, ddGTP, and ddCTP.

68. A method for amplifying a double stranded DNA molecule, comprising:

(a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3'-termini of the first strand of said DNA molecule and said second primer is complementary to a sequence at or near the 3'-termini of the second strand of said DNA molecule;

(b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of a *Thermotoga neapolitana* DNA polymerase, under conditions such that a third DNA molecule complementary to said first strand and a fourth DNA molecule complementary to said second strand are synthesized;

(c) denaturing said first and second strand, and said second and fourth strands with heat; and

(d) repeating steps (a) to (c) one or more times, wherein:

said mutant *Thermotoga neapolitana* DNA polymerase has at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'→5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'→3' exonuclease activity of said DNA polymerase; and (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides.

69. A kit for sequencing a DNA molecule, comprising:

(a) a first container means comprising a mutant *Thermotoga neapolitana* DNA polymerase;

(b) a second container means comprising one or more dideoxynucleoside triphosphates; and

5 (c) a third container means comprising one or more deoxyribonucleoside triphosphates,
wherein:

10 said mutant *Thermotoga neapolitana* DNA polymerase has at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'-5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'-3' exonuclease activity of said DNA polymerase; and (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides.

15 70. A kit for amplifying a DNA molecule, comprising:

(a) a first container means comprising a mutant *Thermotoga neapolitana* DNA polymerase; and

(b) a second container means comprising one or more deoxyribonucleoside triphosphates,

20 wherein:

25 said mutant *Thermotoga neapolitana* DNA polymerase has at least one mutation selected from the group consisting of (1) a first mutation that substantially reduces or eliminates 3'-5' exonuclease activity of said DNA polymerase; (2) a second mutation that substantially reduces or eliminates 5'-3' exonuclease activity of said DNA polymerase; and (3) a third mutation in the O helix of said DNA polymerase resulting in said DNA polymerase becoming non-discriminating against dideoxynucleotides.

1/10




FIG.1

SUBSTITUTE SHEET (RULE 26)

2/10




FIG.2

SUBSTITUTE SHEET (RULE 26)

3/10




FIG.3

SUBSTITUTE SHEET (RULE 26)

4/10




FIG.4

SUBSTITUTE SHEET (RULE 26)

5/10

BamHI

1 GGATCCAGAC TGGTGGATCG TCAGTGGGGA TTATCCCAA ATACAAC TCA GAATCCTCGC
G S R L V D R Q C G L F P N R T Q N P C
→ D P D W W I V S A D Y S Q I E L R I L
I Q T G G S S V R I I P K - N S E S S

61 TCATCTCAGT GGTGATGAGA ACCTTGTGAA GGCCTTCGAG GAGGGCATCG ATGTGCACAC
S S Q W - - E P C E G L R G G H R C A H
→ A H L S G D E N L V K A F E E G I D V H
L I S V V M R T L - R P S R R A S M C T

121 CTTGACTGCC TCCAGGATCT ACAACGTAAA GCCAGAAGAA GTGAACGAAG AAATGCGACG
L D C L Q D L Q R K A R R S E R R N A T
→ T L T A S R I Y N V K P E E V N E E M R
P - L P P G S T T - S Q K K - T K K C D

181 GGTTCGAAG ATGGTGAAC TCTCTATAAT ATACGGTGC ACACCGTAGC GTCTTTCTGT
G W K D G E L L Y N I R C H T V R S F C
→ R V G K M V N (F) S I I Y G V T P Y G L S
G L E R W - T S L - Y T V S H R T V F L

241 GAGACTTGA ATACCGGTA AAGAAGCAGA AAAGATGATT ATCAGCTATT TCACACTGTA
E T W N T G - R S R K D D Y Q L F H T V
→ V R L G I P V K E A E K M I I S Y F T L
- D L E Y R L K K Q K R - L S A I S H C

301 TCCAAAGGTG CGAAGCTACA TCCAGCAGGT TGTTCAGAG GCAAAAGAGA AGGCTACGT
S K G A K L H P A G C C R G K R E G L R
→ Y P K V R S Y I Q Q V V A E A K E K G Y
I Q R C E A T S S R L L Q R Q K R R A T

361 CAGGACTCTC TTTGGAAGAA AAAGAGATAT TCCCAGCTC ATGGCAAGGG ACAAGAACAC
Q D S L W K K K R Y S P A H G K G Q E H
→ V R T L F G R K R D I P Q L M A R D K N
S G L S L E E K E I F P S S W Q G T R T

421 CCAGTCCGAA GGCAGAAAGAA TCGCAATAAA CACCCCATC CAGGGAACG CGGCAGATAT
P V R R R K N R N K H P H S G N C G R Y
→ T Q S E G E R I A I N T P I Q G T A A D
P S P K A K E S Q - T P P F R E L R Q I

FIG.5A

SUBSTITUTE SHEET (RULE 26)

6/10

481 AATAAAATG GCTATGATAG ATATAGACGA GGAGCTGAGA AAAAGAAACA TGAAATCCAG
N K I G Y D R Y R R G A E K K K H E I Q
—→ I I K L A M I D I D E E L R K R N M K S
- - N W L - - I - T R S - E K E T - N P

541 AATGATCATT CAGGTCATG ACGAACTGGT CTTGAGGTT CCCGATGAGG AAAAGAAGA
N D H S G S - R T G L R G S R - G K R R
—→ R M I I Q V H D E L V F E V P D E E K E
E - S F R F M T N W S S R F P M R K K K

601 ACTAGTTGAT CTGGTGAAGA ACAAATGAC AAATGTGGTG AAATCTCTCG TGCCTCTTGA
T S - S G E E Q N D K C G E T L C A S -
—→ E L V D L V K N K M T N V V K L S V P L
N - L I W - R T K - Q M W - N S L C L L

661 GGTGACATA ACGATGGGAA AAAGCTGGTC TTGA
G - H K H R K K L V L
—→ E V D I S I G K S W S -
R L T - A S E K A G L

FIG.5B




FIG.6A

SUBSTITUTE SHEET (RULE 26)

8/10




FIG.6B

SUBSTITUTE SHEET (RULE 26)




FIG.7

SUBSTITUTE SHEET (RULE 26)




FIG.8
SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

 International Application No.
 PCT/US 95/12358

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N15/54 C12N15/70 C12N9/12 C12N1/21 C12Q1/68
 //(C12N1/21, C12R1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ARCHIVES OF MICROBIOLOGY, vol. 150, no. 1, 1988 SPRINGER, BERLIN, BRD, pages 103-104, H.W. JANNASCH ET AL. 'Thermotoga neapolitana sp. nov. of the extremely thermophilic, eubacterial genus Thermotoga' see the whole document --- -/--	1-70

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A document member of the same patent family

Date of the actual completion of the international search

28 February 1996

Date of mailing of the international search report

14.03.96

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 95/12358

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ARCHIVES OF MICROBIOLOGY, vol. 151, no. 6, - 1989 SPRINGER, BERLIN, BRD, pages 506-512, E. WINDBERGER ET AL. 'Thermotoga-thermarum new-species and Thermotoga neapolitana occurring in african continental solfataric springs' cited in the application see the whole document ---	1-70
A	WO,A,92 06202 (CETUS CORP) 16 April 1992 see the whole document ---	1-70
A	WO,A,92 06200 (CETUS CORP) 16 April 1992 see the whole document ---	1-70
A	WO,A,92 03556 (CETUS CORP) 5 March 1992 see the whole document ---	1-70
P,A	EP,A,0 655 506 (HARVARD COLLEGE) 31 May 1995 see the whole document ---	1-70
T	J. BIOL. CHEM., vol. 270, no. 4, 27 January 1995 AM. SOC. BIOCHEM. MOL.BIOL.,INC.,BALTIMORE,US, pages 1945-1954, M. ASTATKE ET AL. 'Deoxynucleoside triphosphate and pyrophosphate binding site in the catalytically competent ternary complex for the polymerase reaction catalyzed by DNA polymerase I (Kleno fragment)' cited in the application see the whole document ---	1-70
T	PROC. NATL.ACAD SCI., vol. 92, 3 July 1995 NATL. ACAD SCI.,WASHINGTON,DC,US;, pages 6339-6343, S. TABOR AND C.C. RICHARDSON 'A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxynucleotides' see the whole document -----	1-70

Form PCT/ISA/214 (continuation of earlier sheet) (July 1977)

INT NATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 95/12358

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9206202	16-04-92	AU-B- 663474	12-10-95
		AU-B- 8668891	28-04-92
		AU-B- 658378	13-04-95
		AU-B- 8907791	28-04-92
		CA-A- 2090614	29-03-92
		CA-A- 2092317	29-03-92
		EP-A- 0550687	14-07-93
		EP-A- 0550696	14-07-93
		JP-T- 6504196	19-05-94
		WO-A- 9206200	16-04-92
		US-A- 5466591	14-11-95
WO-A-9206200	16-04-92	AU-B- 663474	12-10-95
		AU-B- 8668891	28-04-92
		CA-A- 2090614	29-03-92
		EP-A- 0550687	14-07-93
		US-A- 5405774	11-04-95
		US-A- 5466591	14-11-95
		US-A- 5455170	03-10-95
		AU-B- 658378	13-04-95
		AU-B- 8907791	28-04-92
		CA-A- 2092317	29-03-92
		EP-A- 0550696	14-07-93
		JP-T- 6504196	19-05-94
		WO-A- 9206202	16-04-92
WO-A-9203556	05-03-92	US-A- 5374553	20-12-94
		AU-B- 653747	13-10-94
		AU-B- 8501491	17-03-92
		CA-A- 2089495	14-02-92
		DE-T- 544789	16-12-93
		EP-A- 0544789	09-06-93
		JP-A- 7147990	13-06-95
		JP-B- 7108220	22-11-95
		JP-T- 6500020	06-01-94
		US-A- 5420029	30-05-95
EP-A-0655506	31-05-95	DE-U- 29513622	19-10-95
		DE-U- 29513639	19-10-95
		DE-T- 655506	28-09-95

Information on patient family members

PCT/US 95/12358

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0655506		ES-T- 2072238	16-07-95